Show results for
Refine by
Preclinical Modeling Suppliers Serving Latvia
31 companies found
based inKøbenhavn N, DENMARK
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ...
based inHerzliya, ISRAEL
elminda was founded in 2006 with the goal of addressing the unmet needs of people suffering from brain related disorders. Our mission: perfect a technology that would reveal an individual’s unique brain function “signatures” or “fingerprints,” ...
CNS drugs exhibit the lowest approval success rates due to multiple challenges such as lack of efficacy in early and advanced stages of development, Poor target selection / engagement, poor translation from pre-clinical models and disease ...
based inUnion City, CALIFORNIA (USA)
Fibralign is an award-winning, commercial-stage, Stanford-spinout that designs, develops and produces novel therapeutic medical devices to address major unmet medical needs. Based in the San Francisco Bay Area, the company’s team has established GMP ...
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means ...
based inBerlin, GERMANY
Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: developing precision medicine to rescue vascular integrity and saving the lives of critically ill patients with limited treatment options. The ...
The Company’s lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
INOVOTION has developed a unique, highly sensitive and reproducible assay. It is applicable to all preclinical oncology and immuno-oncology drug discovery programs, and monitors the growth and metastatic dissemination of human tumor ...
based inCambridge, UNITED KINGDOM
We’re driven by the shared purpose of breaking new ground in the discovery of new treatments for rare diseases. Healx is a mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to ...
Our Rare Treatment Accelerator helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to ...
based inBerwyn, PENNSYLVANIA (USA)
Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery systems across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate. Our transforming ...
Endogenous peptides with analgesic potential include endorphins via binding to the mu receptor, dynorphins via the kappa receptor and enkephalins via the delta receptor. Kappa and delta opioid agonists have been shown to provide analgesic benefit ...
based inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
This is the best tool you can use to evaluate new therapeutic approaches in conditions that are as close as possible to a clinical situation: ...
based inSan Diego, CALIFORNIA (USA)
Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients by reducing the time and expense needed to bring these medicines to patients. We do this by generating ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Pimitespib (TAS-116) is an oral bioavailable, ATP-competitive, highly specific HSP90α/HSP90β inhibitor (Kis of 34.7 nM and 21.3 nM, respectively) without inhibiting other HSP90 family proteins such as GRP94[1]. Pimitespib demonstrates less ocular ...
based inLondon, UNITED KINGDOM
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in orphan diseases, ...
based inCambridge, MASSACHUSETTS (USA)
Myeloid Therapeutics is a leader in the development of mRNA-based immunotherapies, focusing on harnessing and enhancing the natural capabilities of myeloid cells to combat cancer. The company's cutting-edge in vivo engineering platform is designed ...
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third leading cause of ...
based inHeerlen, NETHERLANDS
DSM is a global purpose-led, science-based company specializing in Nutrition, Health & Sustainable Living. Our purpose is to create brighter lives for all. We achieve it by using all the scientific and innovation power at our disposal to tackle some ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
based inSeattle, WASHINGTON (USA)
Nexelis is your partner for assay and biomarker development, advanced bioanalytical and laboratory testing, and translational immunology. As the leading specialty laboratory, we have unrivaled expertise in immunology, specifically in the areas of ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Innovative antibody-based molecular concepts. New treatments for cancer that leverage our own immune system to attack and destroy cancer cells can provide long-term and durable therapeutic responses in patients suffering from life-threatening ...
based inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
based inBillerica, MASSACHUSETTS (USA)
Access Vascular is offering a suite of vascular access devices that use our novel, patented biomaterial featuring MIMIX™ technology which is designed to prevent the most common and costly complications in vascular access. Keep treatment moving ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a ...
based inSouth Melbourne, AUSTRALIA
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...
BDM-I: Addressing market need for next-generation antimicrobials. Infectious diseases often dominate the media headlines, including rising antibiotic resistance and fear of “super bugs”. One serious problem facing the global community is ...